Literature DB >> 2354092

Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine.

M H Hanna1, S J Peat, M Woodham, A Knibb, C Fung.   

Abstract

The analgesic efficacy and CSF pharmacokinetics of intrathecal morphine sulphate and morphine-6-glucuronide (M6G) were compared in a single-blind crossover study. Lumbar intrathecal catheters were sited in three patients with chronic cancer pain, and morphine sulphate 500 micrograms or M6G 500 micrograms given via the catheter on separate days. CSF was sampled for 24 h following drug administration and analysed for morphine and M6G by high pressure liquid chromatography. The mean (SD) requirement for patient controlled analgesia with pethidine was 393.3 (227.4) mg/24 h during the morphine limb of the trial and 226.7 (113.6) mg/24 h during the M6G limb. M6G was not detected in CSF following administration of morphine. Fitting of CSF concentrations to triexponential curves revealed mean (SD) alpha, beta and gamma half-lives of 13.2 (7.4), 54.9 (31.5) and 222.5 (100) min for morphine and 11.2 (2.4), 67.3 (49.9) and 619.3 (629.7) min for M6G.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354092     DOI: 10.1093/bja/64.5.547

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  24 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  Blood-brain distribution of morphine-6-glucuronide in sheep.

Authors:  H H Villesen; D J R Foster; R N Upton; L L Christrup; A A Somogyi; A Martinez; C Grant
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 5.  Palliative care.

Authors:  C L Davis; J R Hardy
Journal:  BMJ       Date:  1994-05-21

Review 6.  Neuraxial morphine and respiratory depression: finding the right balance.

Authors:  Pervez Sultan; Maria Cristina Gutierrez; Brendan Carvalho
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

7.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  An in vitro study of diamorphine permeation through premature human neonatal skin.

Authors:  D A Barrett; N Rutter; S S Davis
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

9.  Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration.

Authors:  H Quiding; G L Olsson; L O Boreus; U Bondesson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 10.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.